Trial Profile
A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dinaciclib (Primary) ; MK 2206 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- 21 Aug 2017 Status changed from active, no longer recruiting to completed.
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.